Abstract:Objective:To re-evaluate the clinical efficacy and safety of Longfengbao tablets for the treatment of perimenopausal syndrome. Method: Eighty-four patients were randomly divided into treatment group and control group (n=42 each). The control group was treated with livial 2.5 mg daily; the treatment group was orally given Longfengbao tablets 1.2 g tid. The treatment lasted for 12 weeks. Kupperman score, serum estradiol (E2), follicle stimulating hormone (FSH), luteinizing hormone (LH) l, endometrial thickness were measured and traditional Chinese medicine clinical symptom score were compared between the two groups. Result: After the treatment, the two sets of the Kupperman ratings and deficiency syndrome integral were significantly lowered than before (P<0.01), the deficiency syndrome points of the treatment group was lower than that of the control group(P<0.01). Serum E2 level in two groups was significantly increased after treatment (P<0.01). The effective rate of the treatment group was 88.09% while the control group was 92.85%; the endometrial thickness did not change significantly after the treatment in both groups. The treatment group showed no adverse reactions. Conclusion: Longfengbao tablets can significantly improve the clinical symptoms of perimenopause syndrome, reduce the Kupperman score, elevated serum E2 levels without increasing endometrial thickness, and it is safe and effective.
